Orris

Answer this questions in detail

Reading File
I need to first read the PDF to see what questions are in it before answering them. Let me extract the content.
Running Command

cd /tmp/workspace/attachments/35614c4a-cf90-44a9-bd6e-66aefc79165e && python3 -c " import pdfplumber with pdfplumber.open('PHARMACOLOGY PAPER 2 CHAPTEWISE PYQs.pdf') as pdf: print(f'Total pages: {len(pdf.pages)}') for i, page in enumerate(pdf.pages[:5]): print(f'\\n=== PAGE {i+1} ===') print(page.extract_text()) "

Running Command

cd /tmp/workspace/attachments/35614c4a-cf90-44a9-bd6e-66aefc79165e && python3 -c " import pdfplumber with pdfplumber.open('PHARMACOLOGY PAPER 2 CHAPTEWISE PYQs.pdf') as pdf: for i, page in enumerate(pdf.pages[5:]): print(f'\\n=== PAGE {i+6} ===') print(page.extract_text()) "

The PDF contains a large question bank across many chapters. I need to clarify which questions the user wants answered, as there are dozens across 9 pages.
Asking for Preferences

The PDF contains a large question bank across many chapters. Which questions would you like me to answer?

Reading File
Given the enormous scope (the entire PDF has hundreds of questions across all of pharmacology), I'll now deliver comprehensive, detailed answers to ALL questions, organized chapter by chapter. I'll use my medical knowledge (which is very strong for pharmacology) supplemented by library searches.Given the very large number of questions and limited budget, I'll now write the full detailed answers for all sections in one comprehensive response.

PHARMACOLOGY PAPER II - COMPLETE ANSWERS

SECTION I: CENTRAL NERVOUS SYSTEM (CNS)

CHAPTER: ALCOHOLS

Q. Why is Ethyl Alcohol used in Methyl Alcohol Poisoning?

Methyl alcohol (methanol) toxicity is due to its metabolic products, not methanol itself.
Metabolism of Methanol:
  • Methanol → (Alcohol dehydrogenase) → Formaldehyde → (Aldehyde dehydrogenase) → Formic acid
  • Formic acid causes severe metabolic acidosis and optic nerve toxicity (blindness).
Basis of using Ethanol:
  1. Competitive substrate: Ethanol has 10-20x greater affinity for alcohol dehydrogenase compared to methanol.
  2. Competitive inhibition: By providing ethanol, the enzyme is saturated with ethanol, preventing methanol from being metabolized.
  3. Methanol remains unmetabolized and is excreted unchanged via lungs and kidneys.
  4. This prevents formation of the toxic metabolites formaldehyde and formic acid.
Target blood ethanol level: 100-150 mg/dL (maintained by IV infusion or oral administration).
Alternative: Fomepizole (4-methylpyrazole) - a direct alcohol dehydrogenase inhibitor, now preferred but expensive.
Additional treatment: Sodium bicarbonate (to correct acidosis), Folinic acid (enhances formate metabolism), Haemodialysis (in severe cases).

CHAPTER: SEDATIVES AND HYPNOTICS

Q. Reasons behind Drug Automatism seen with Barbiturates

Drug automatism = The patient takes repeated doses of a hypnotic drug because they cannot remember whether they took it or not (due to drug-induced sedation/amnesia), leading to overdose.
Reasons specific to barbiturates:
  1. Anterograde amnesia: Barbiturates impair memory formation, so the patient forgets they already took the drug.
  2. Short duration of action (especially short-acting barbiturates): The patient wakes during the night and takes another dose.
  3. Narrow therapeutic index: Small overdose leads to significant toxicity (respiratory depression, coma).
  4. No ceiling effect: Unlike benzodiazepines, barbiturates can cause dose-dependent progressive CNS depression.
  5. Tolerance development: Leads to dose escalation, increasing risk of accidental overdose.
This is why barbiturates have largely been replaced by benzodiazepines for routine sedation.

Q. Three Differences Between Barbiturates and Benzodiazepines

FeatureBarbituratesBenzodiazepines
MechanismOpen Cl⁻ channel directly (increase duration of opening) AND act at GABA-A receptor by increasing frequency AND can directly activate at high dosesIncrease frequency of Cl⁻ channel opening (allosteric modulation of GABA-A) - GABA-dependent
Safety / Therapeutic IndexNarrow; overdose causes fatal respiratory depressionWide; overdose rarely fatal alone
Selectivity of CNS depressionNon-selective; depresses all areas including RASMore selective; anxiolysis at low doses
Drug automatismHigh riskLow risk (causes amnesia less severely)
AntidoteNone specificFlumazenil (specific antagonist)
Enzyme inductionPotent inducers of CYP450Minimal enzyme induction
DependenceHigh physical and psychological dependenceLess (still present)
(Three of the above differences are sufficient.)

Q. Why Benzodiazepines are Preferred Over Barbiturates as Sedative-Hypnotics

  1. Greater safety margin (wider therapeutic index): Benzodiazepines cannot directly open Cl⁻ channels - they only enhance GABA-mediated activity. Therefore, even in overdose, they cannot produce deep CNS depression without endogenous GABA.
  2. Specific antidote available: Flumazenil can reverse benzodiazepine toxicity; no antidote for barbiturates.
  3. Less drug automatism: Less severe amnesia.
  4. Less respiratory depression: At therapeutic doses.
  5. No enzyme induction: Do not accelerate metabolism of co-administered drugs.
  6. Less abuse potential (comparatively).
  7. Less severe withdrawal (comparatively, though withdrawal can still be serious).
  8. Preserve normal sleep architecture better (less REM suppression with modern BZDs).

Q. Z Compounds (Z-Drugs)

Z-drugs are non-benzodiazepine hypnotics that act on BZD receptors (GABA-A), but are chemically distinct.
Examples: Zolpidem, Zopiclone, Zaleplon, Eszopiclone ("Z" compounds)
Mechanism: Selective agonists at BZD₁ (ω₁) receptor subtype → predominantly sedative-hypnotic effect with minimal anxiolysis, muscle relaxation, or anticonvulsant effect.
Advantages over BZDs:
  • Shorter half-life (Zolpidem: 2-3 hrs; Zaleplon: ~1 hr)
  • Minimal rebound insomnia
  • Less tolerance and dependence
  • Preserve sleep architecture better (less REM suppression)
  • Useful for sleep-onset insomnia (Zaleplon) and sleep-maintenance insomnia (Zolpidem, Zopiclone)
Adverse effects: Anterograde amnesia, sleepwalking, parasomnia, next-day drowsiness.

CHAPTER: ANTIEPILEPTIC DRUGS

Q. Classify Antiepileptic Drugs; Mechanism, Uses, and Adverse Effects of Phenytoin Sodium; Newer AEDs

Classification of Antiepileptic Drugs

By Mechanism:
MechanismDrugs
Na⁺ channel blockersPhenytoin, Carbamazepine, Valproate, Lamotrigine, Oxcarbazepine, Topiramate
Ca²⁺ channel blockers (T-type)Ethosuximide, Valproate
GABA enhancement (↑ GABA-A action)Benzodiazepines (Diazepam, Clonazepam), Barbiturates (Phenobarbitone), Vigabatrin (GABA-T inhibitor), Tiagabine (GAT-1 inhibitor)
Glutamate antagonism (AMPA)Topiramate, Perampanel
Multiple mechanismsValproate, Topiramate, Lamotrigine
Synaptic vesicle protein SV2ALevetiracetam
HCN channel blockerGabapentin, Pregabalin
By Use (Seizure Type):
Seizure TypeFirst-line Drugs
Generalised tonic-clonic (GTC)Valproate, Phenytoin, Carbamazepine, Lamotrigine
Partial/focal seizuresCarbamazepine, Phenytoin, Oxcarbazepine, Levetiracetam
Absence seizuresEthosuximide, Valproate
Myoclonic seizuresValproate, Levetiracetam, Clonazepam
Status epilepticusIV Diazepam/Lorazepam → IV Phenytoin/Fosphenytoin → IV Valproate → General anaesthesia

Phenytoin Sodium

Mechanism of Action:
  • Phenytoin blocks voltage-gated sodium channels in a use-dependent (frequency-dependent) manner.
  • It preferentially binds to and stabilizes the inactivated state of Na⁺ channels.
  • This prevents repetitive high-frequency firing of neurons (as occurs in seizures) without affecting normal low-frequency firing.
  • Also inhibits Ca²⁺ entry and reduces glutamate release at high concentrations.
Therapeutic Uses:
  1. Epilepsy: GTC seizures, partial seizures (simple and complex), Status epilepticus (IV fosphenytoin)
  2. Trigeminal neuralgia (second line after carbamazepine)
  3. Cardiac arrhythmias: Especially digoxin-induced arrhythmias (due to Na⁺ channel blockade)
  4. Neuropathic pain
Adverse Effects:
Dose-related (concentration-dependent):
  • Nystagmus (first sign, at serum level ~20 µg/mL)
  • Ataxia, diplopia, vertigo
  • Cognitive impairment
  • Seizure aggravation (at toxic levels)
Dose-independent (idiosyncratic/chronic):
  • Gingival hyperplasia (20-30%) - due to fibroblast proliferation; poor dental hygiene worsens it
  • Hirsutism (especially in women)
  • Coarsening of facial features
  • Peripheral neuropathy (demyelination)
  • Megaloblastic anaemia (interferes with folate absorption)
  • Osteomalacia (induces CYP450 → increased vitamin D metabolism)
  • Teratogenicity: Fetal hydantoin syndrome (cleft palate, cardiac defects, digit/nail hypoplasia)
  • Stevens-Johnson syndrome (rare, idiosyncratic)
  • Hypersensitivity reactions
Pharmacokinetic peculiarity:
  • Zero-order (saturation) kinetics at therapeutic doses: small increase in dose leads to disproportionate rise in plasma levels and toxicity (see below).

Q. Change in Elimination Kinetics of Phenytoin from First-Order to Zero-Order - Clinical Significance

Normal (First-order) kinetics: Rate of elimination is proportional to drug concentration; constant fraction eliminated per unit time; linear relationship between dose and plasma levels.
Zero-order kinetics: Rate of elimination is constant and independent of concentration; a fixed amount eliminated per unit time (enzyme is saturated).
Why Phenytoin switches:
  • Phenytoin is metabolized by CYP2C9/CYP2C19 (hepatic hydroxylation) - a saturable enzyme system.
  • At low doses: First-order kinetics; plasma levels increase proportionally with dose.
  • As therapeutic doses are approached, the enzyme becomes saturated (Km is within the therapeutic range).
  • Above saturation: Zero-order kinetics - elimination becomes constant, regardless of dose.
Clinical Significance:
  1. Small dose increments at therapeutic levels cause disproportionately large rises in plasma concentration → toxicity risk.
  2. Long time to reach steady state after any dose change (can take weeks).
  3. Narrow therapeutic window (10-20 µg/mL) requires therapeutic drug monitoring (TDM).
  4. Drug interactions are particularly dangerous as they can push levels into toxic range suddenly.
  5. Half-life is not constant - it increases as dose increases.

Q. Compare Phenytoin Sodium and Valproic Acid as Antiepileptic Drugs

FeaturePhenytoin SodiumValproic Acid (Sodium Valproate)
MechanismNa⁺ channel blocker (inactivated state)Multiple: Na⁺ channel blockade + T-Ca²⁺ block + GABA increase (inhibits GABA-T and GAD)
SpectrumFocal/partial + GTC; NOT effective in absenceBroad spectrum: GTC, partial, absence, myoclonic, atonic
KineticsZero-order at therapeutic range; highly protein-bound (90%)First-order; also highly protein-bound (90%); linear kinetics
Key ADEsGingival hyperplasia, hirsutism, fetal hydantoin syndrome, nystagmusHepatotoxicity, teratogenicity (neural tube defects), weight gain, hair loss (alopecia), tremor, thrombocytopenia
TeratogenicityFetal hydantoin syndrome (FDA Category D)Neural tube defects (spina bifida) - especially dangerous (FDA Category D, avoid in women of childbearing age)
Drug interactionsPotent enzyme inducer (CYP450) - reduces levels of many drugsEnzyme inhibitor - increases levels of Phenobarbitone, Lamotrigine
Use in absenceNot useful (may worsen)First choice
AntidoteNoneNone

Q. Why Sodium Valproate is a Broad-Spectrum Antiepileptic Drug

Valproate is called broad-spectrum because it is effective against virtually all types of seizures:
  • Generalized tonic-clonic seizures
  • Absence seizures (petit mal)
  • Myoclonic seizures
  • Atonic/akinetic seizures
  • Partial/focal seizures
  • Infantile spasms (West syndrome)
  • Status epilepticus (IV formulation)
Reason for broad spectrum - multiple mechanisms:
  1. Na⁺ channel blockade (inactivated state) - GTC, focal seizures
  2. T-type Ca²⁺ channel blockade - absence seizures (thalamo-cortical circuit)
  3. Increased GABA levels:
    • Inhibits GABA transaminase (GABA-T) → reduces GABA breakdown
    • Increases glutamic acid decarboxylase (GAD) activity → increases GABA synthesis
  4. Reduced glutamate (excitatory neurotransmitter) release
This multi-mechanism action makes it effective across seizure types.

Q. Non-Epileptic Uses of Carbamazepine

  1. Trigeminal neuralgia - drug of choice; relieves lancinating facial pain
  2. Glossopharyngeal neuralgia
  3. Bipolar disorder (Mania) - mood stabilizer, especially in rapid-cycling bipolar
  4. Schizophrenia - adjunct
  5. Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia)
  6. Alcohol withdrawal seizures
  7. Diabetes insipidus (nephrogenic - partial effect; enhances ADH action)
  8. SIADH (high doses can cause SIADH; low dose used in some cases)

Q. Absence Seizures - Two Suitable Drugs

  1. Ethosuximide - drug of choice for pure absence seizures; mechanism: blocks T-type Ca²⁺ channels in thalamo-cortical neurons
  2. Sodium Valproate - drug of choice when absence is accompanied by other seizure types (broader spectrum)
Note: Carbamazepine and Phenytoin are contraindicated in absence seizures as they may worsen them.

Q. Adverse Effects of Phenytoin

(Covered above in detail; key points:)
  • Nystagmus, ataxia, diplopia (dose-related)
  • Gingival hyperplasia
  • Hirsutism, coarsening of facial features
  • Megaloblastic anaemia (folate deficiency)
  • Osteomalacia (vitamin D deficiency via CYP induction)
  • Fetal hydantoin syndrome (teratogenicity)
  • Stevens-Johnson syndrome
  • Peripheral neuropathy
  • Lymphadenopathy (pseudolymphoma)

Q. Classify Antiepileptic Drugs - Write Uses and Adverse Effects of Phenytoin (2023)

(Refer to above - Classification + Phenytoin sections)

Q. Classify AEDs by Mechanism of Action; Write on Sodium Valproate MOA; Five Non-Epileptic Uses; Treatment of Status Epilepticus (2025 Jan - Case: 40-yr male with jerking limbs/convulsions)

(Classification covered above)
Mechanism of Sodium Valproate:
  1. Blocks voltage-gated Na⁺ channels (inactivated state) - reduces neuronal firing
  2. Blocks T-type Ca²⁺ channels - interrupts thalamo-cortical oscillations (absence seizures)
  3. Inhibits GABA-transaminase (GABA-T) - reduces GABA catabolism, raises GABA levels
  4. Increases glutamic acid decarboxylase activity - increases GABA synthesis
  5. Reduces glutamate release (antiexcitatory)
Five Non-Epileptic Uses of Sodium Valproate:
  1. Bipolar disorder (mood stabilizer - both mania and bipolar depression)
  2. Migraine prophylaxis (reduces frequency of attacks)
  3. Neuropathic pain
  4. PTSD (Post-traumatic stress disorder)
  5. Schizophrenia (augmentation)
Treatment of Status Epilepticus (SE):
Status epilepticus = continuous seizures >5 minutes or two/more seizures without recovery between them.
Step-wise management:
  1. Airway, Breathing, Circulation (ABC); IV access; monitor vitals; IV glucose if hypoglycaemia
  2. 0-5 min: Benzodiazepines (first-line):
    • IV Lorazepam 0.1 mg/kg (preferred) OR IV Diazepam 0.15-0.2 mg/kg
    • IM Midazolam (if no IV access)
  3. 5-20 min: If seizures continue - Second line:
    • IV Fosphenytoin (or Phenytoin) - 20 mg PE/kg at 150 mg/min
    • OR IV Valproate - 40 mg/kg IV
    • OR IV Levetiracetam - 60 mg/kg IV
  4. 20-40 min: Refractory SE - Third line:
    • Repeat fosphenytoin/valproate/levetiracetam (whichever not used)
  5. >40 min: Super-refractory SE:
    • Anaesthetic doses: IV Midazolam infusion, IV Propofol infusion, IV Thiopentone (barbiturate coma)
    • Ketamine, Inhaled anaesthetics
    • Require mechanical ventilation and ICU care

Q. Write the Basis of Use of Valproate in Epilepsy (2024 April)

(The multi-mechanism basis is detailed above in the "Why Sodium Valproate is broad spectrum" section.)

CHAPTER: ANTIPARKINSONIAN DRUGS

Q. Explain the Rationale/Advantages of Combining Levodopa with Carbidopa

Parkinson's Disease: Degeneration of dopaminergic neurons in substantia nigra pars compacta → deficiency of dopamine in striatum → imbalance between dopamine (inhibitory) and acetylcholine (excitatory) → motor symptoms.
Why Levodopa instead of Dopamine?
  • Dopamine cannot cross the blood-brain barrier (BBB).
  • Levodopa (L-DOPA) crosses the BBB via L-amino acid transporter.
Problem with Levodopa alone:
  • More than 95% of oral levodopa is decarboxylated in the periphery (gut, liver, kidney) by DOPA decarboxylase (aromatic L-amino acid decarboxylase - AADC) to form dopamine.
  • This peripheral dopamine causes:
    • Nausea, vomiting (stimulates CTZ)
    • Hypotension (postural)
    • Cardiac arrhythmias
    • Only 1-3% of levodopa actually enters the brain.
Carbidopa:
  • Carbidopa is a peripheral DOPA decarboxylase inhibitor that does NOT cross the BBB.
  • When combined with levodopa:
    1. Prevents peripheral decarboxylation of levodopa to dopamine.
    2. More levodopa reaches the brain (bioavailability increases ~3-5 fold).
    3. Dose of levodopa can be reduced by 75% (reducing side effects).
    4. Peripheral side effects (nausea, vomiting, hypotension) are dramatically reduced.
    5. Onset of action is faster.
    6. Prevents vitamin B6 reversal (pyridoxine no longer reverses effect, as B6-dependent peripheral decarboxylase is blocked).
Fixed-dose combinations available: Syndopa (Levodopa + Carbidopa), Sinemet, Mucuna (with Benserazide - another peripheral DDC inhibitor).

Q. Drugs for Treatment of Drug-Induced Parkinsonism

Drug-induced parkinsonism is caused by dopamine receptor blockers (antipsychotics, metoclopramide).
Treatment:
  1. Stop the offending drug (if possible) - symptoms usually resolve in weeks to months.
  2. Anticholinergic drugs (first choice for drug-induced parkinsonism):
    • Trihexyphenidyl (Benzhexol)
    • Benztropine (Cogentin)
    • Biperiden
  3. Amantadine (if anticholinergics fail)
  4. Levodopa is NOT used because the dopamine receptors are blocked and levodopa would be ineffective (see below).

Q. Why Levodopa is NOT Used in Drug-Induced Parkinsonism

  • Drug-induced parkinsonism (e.g., from antipsychotics/neuroleptics/metoclopramide) is due to blockade of D2 dopamine receptors in the striatum.
  • Adding levodopa increases dopamine levels, but since the receptors are already blocked, the extra dopamine cannot bind to or stimulate D2 receptors.
  • Levodopa is therefore ineffective.
  • Furthermore, levodopa may worsen the psychiatric condition (if antipsychotic was given for psychosis).
  • Anticholinergics (which restore the acetylcholine-dopamine balance) are preferred.

Q. Why Bromocriptine is Effective Even After Levodopa Fails in Parkinsonism

Levodopa failure ("wearing off" or L-DOPA resistance):
  • After prolonged levodopa therapy, presynaptic dopaminergic neurons continue to degenerate.
  • The remaining neurons lose capacity to uptake, store, and convert levodopa to dopamine.
  • Additionally, dopamine receptors may downregulate.
Bromocriptine:
  • Bromocriptine is a direct dopamine agonist (D2 receptor agonist primarily, also D1).
  • It directly stimulates postsynaptic dopamine receptors without needing presynaptic terminals.
  • Therefore, even when presynaptic neurons have degenerated and cannot convert levodopa to dopamine, bromocriptine can directly activate dopamine receptors.
  • Also has longer half-life than levodopa → reduces "on-off" fluctuations.
Other dopamine agonists: Pramipexole, Ropinirole, Rotigotine, Cabergoline.

Q. Why Pyridoxine Should Be Avoided in Patients on Levodopa Therapy

Pyridoxine (Vitamin B6):
  • Pyridoxal phosphate (active form of B6) is a cofactor for DOPA decarboxylase (AADC).
  • Giving pyridoxine enhances peripheral DOPA decarboxylase activity.
  • This increases peripheral conversion of levodopa to dopamine → less levodopa reaches the brain → loss of therapeutic effect.
  • Peripheral dopamine increases → more side effects (nausea, hypotension).
Exception: If levodopa is given WITH carbidopa (peripheral DDC inhibitor), pyridoxine does NOT reduce its effect, because peripheral DDC is already inhibited. So the warning applies specifically to levodopa alone (without carbidopa).

Q. What is "On-Off" Phenomenon and Which Drugs are Combined to Overcome It

On-Off Phenomenon:
  • A complication of long-term levodopa therapy.
  • "On" period: Levodopa is effective; patient has good motor function.
  • "Off" period: Sudden, unpredictable loss of effect; patient experiences severe motor deterioration, freezing, rigidity.
  • Mechanism: Relates to shortened duration of levodopa action over time + pulsatile dopaminergic stimulation.
Drugs to overcome on-off phenomenon:
  1. COMT inhibitors (extend levodopa action by reducing peripheral catabolism):
    • Entacapone (added to each levodopa dose) or Tolcapone
    • Combined as Stalevo (Levodopa + Carbidopa + Entacapone)
  2. MAO-B inhibitors (reduce dopamine breakdown in striatum):
    • Selegiline (Deprenyl), Rasagiline, Safinamide
  3. Dopamine agonists (smooth, long-lasting stimulation):
    • Pramipexole, Ropinirole, Cabergoline
  4. Apomorphine (subcutaneous injection for acute off episodes - rapid rescue)
  5. Continuous intestinal infusion of levodopa-carbidopa gel (Duodopa)

Q. Classify Antiparkinsonian Drugs; Discuss Dopamine Agonists vs Levodopa/Carbidopa (2024 April Case)

Classification of Antiparkinsonian Drugs

  1. Dopamine precursors: Levodopa (always with carbidopa/benserazide)
  2. Dopamine agonists:
    • Ergot derivatives: Bromocriptine, Cabergoline, Pergolide
    • Non-ergot (preferred): Pramipexole, Ropinirole, Rotigotine (patch), Piribedil
  3. MAO-B inhibitors: Selegiline, Rasagiline, Safinamide
  4. COMT inhibitors: Entacapone, Tolcapone
  5. Anticholinergics: Trihexyphenidyl, Benztropine, Biperiden
  6. NMDA antagonist: Amantadine (also dopamine releaser/uptake inhibitor)
  7. Adenosine A2A antagonist: Istradefylline (newer)

Dopamine Agonists vs Levodopa/Carbidopa

FeatureDopamine AgonistsLevodopa + Carbidopa
MechanismDirect stimulation of D2/D3 receptorsPrecursor → converted to dopamine in brain
EfficacyLess potent (monotherapy)Gold standard; most effective
Motor complicationsLower risk of dyskinesias and wearing-offHigher risk (especially after 5 years)
Pulsatile stimulationContinuous stimulation (longer t½)Pulsatile (short t½) → motor fluctuations
Used whenEarly disease (as monotherapy to delay levodopa); adjunct in advanced diseaseAll stages; mainstay treatment
ADEsHallucinations, impulse control disorders (gambling, hypersexuality), somnolence, orthostatic hypotension, nausea; ergot types: fibrosisDyskinesias (on), on-off fluctuations, nausea (less with carbidopa), hypotension
First-line in young patientsPreferred (to delay levodopa-induced dyskinesias)Preferred in elderly (tolerates agonist ADEs poorly)

CHAPTER: ANTIPSYCHOTIC DRUGS (NEUROLEPTICS)

Q. Classify Antipsychotic Drugs; Important Adverse Effects and Drug-Drug Interactions

Classification

Typical (First-Generation) Antipsychotics - D2 receptor blockers:
  • Phenothiazines:
    • Aliphatic: Chlorpromazine, Triflupromazine
    • Piperidine: Thioridazine, Mesoridazine
    • Piperazine: Trifluoperazine, Fluphenazine, Perphenazine
  • Butyrophenones: Haloperidol, Droperidol
  • Thioxanthenes: Thiothixene, Flupenthixol
  • Diphenylbutylpiperidines: Pimozide
Atypical (Second-Generation) Antipsychotics:
  • Dibenzodiazepines: Clozapine
  • Thienobenzodiazepine: Olanzapine
  • Benzisoxazole: Risperidone, Paliperidone
  • Dibenzothiazepine: Quetiapine
  • Benzamide: Amisulpride
  • Quinolinone: Aripiprazole (partial D2 agonist), Brexpiprazole
  • Benzisothiazolylpiperazine: Ziprasidone
  • Tetracyclic: Asenapine
  • Newer: Lurasidone, Cariprazine, Lumateperone

Adverse Effects of Antipsychotics

A. Extrapyramidal Side Effects (EPSE) - mainly with typical:
  1. Acute dystonia (1-5 days): Muscle spasm (torticollis, oculogyric crisis, opisthotonus) - treat with anticholinergics (Benztropine IM)
  2. Akathisia (days-weeks): Restlessness, inability to sit still - treat with Propranolol, Benzodiazepines
  3. Parkinsonism (weeks-months): Bradykinesia, rigidity, tremor - treat with anticholinergics/Amantadine
  4. Tardive Dyskinesia (TD) (months-years): Involuntary oro-facial movements; persistent even after stopping drug - treat with Valbenazine, Deutetrabenazine (VMAT2 inhibitors); Clonazepam
B. Metabolic Effects (mainly atypical - especially Clozapine, Olanzapine):
  • Weight gain (Olanzapine, Clozapine >> Quetiapine > Risperidone)
  • Hyperglycaemia / new-onset diabetes
  • Dyslipidaemia (↑ triglycerides)
C. Anticholinergic Effects (more with Clozapine, Chlorpromazine):
  • Dry mouth, urinary retention, constipation, blurred vision, tachycardia
D. Antiadrenergic Effects:
  • Orthostatic hypotension, reflex tachycardia, sexual dysfunction
E. Neuroleptic Malignant Syndrome (NMS):
  • Life-threatening; hyperthermia, muscular rigidity, altered consciousness, autonomic instability
  • High CK levels
  • Treat: Discontinue drug; Dantrolene, Bromocriptine, Supportive care
F. Prolactin elevation (all D2 blockers except Aripiprazole, Quetiapine):
  • Galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction
G. Clozapine-specific:
  • Agranulocytosis (1-2%) - requires weekly/biweekly WBC monitoring; potentially fatal
  • Seizures (lowers seizure threshold)
  • Hypersalivation (sialorrhoea)
  • Myocarditis (first 4-8 weeks)
H. QTc Prolongation (especially Thioridazine, Ziprasidone, Haloperidol, Amisulpride):
  • Risk of Torsade de pointes, ventricular arrhythmias
Drug-Drug Interactions:
  1. CNS depressants (alcohol, opioids, benzodiazepines) + antipsychotics → enhanced CNS depression
  2. Anticholinergics + Clozapine/Chlorpromazine → additive anticholinergic toxicity
  3. Antihypertensives → enhanced hypotension
  4. QTc prolonging drugs (macrolides, fluoroquinolones, TCAs) + antipsychotics → Torsade de pointes
  5. Enzyme inducers (Carbamazepine, Rifampicin) → reduced antipsychotic plasma levels
  6. Enzyme inhibitors (Fluoxetine, Fluvoxamine) → increased antipsychotic levels (esp. Clozapine, Haloperidol)
  7. Levodopa + antipsychotics → antagonism (both compete for dopamine)
  8. Lithium + Haloperidol → neurotoxicity, NMS risk

Q. Enumerate Atypical Antipsychotic Drugs and Their Advantages Over Typical Antipsychotics

Atypical Antipsychotics: Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone, Amisulpride, Paliperidone, Lurasidone, Asenapine, Cariprazine
Why "Atypical"? - Atypicals have lower D2 receptor occupancy in striatum but higher affinity for other receptors (5-HT2A, D4, H1, muscarinic).
Advantages over Typical Antipsychotics:
  1. Much lower risk of EPS (extrapyramidal side effects):
    • Due to combined D2 + 5-HT2A blockade (serotonin-dopamine antagonism)
    • 5-HT2A blockade in striatum promotes dopamine release, counteracting D2 blockade
  2. Lower risk of tardive dyskinesia (TD) - major advantage, especially for long-term use
  3. Effective against negative symptoms of schizophrenia:
    • Negative symptoms: social withdrawal, flat affect, alogia, avolition
    • Typicals only treat positive symptoms; atypicals treat both positive and negative
  4. Better for treatment-resistant schizophrenia:
    • Clozapine is gold standard for treatment-resistant cases
  5. Lower prolactin elevation (except Risperidone, Amisulpride which do elevate prolactin)
  6. Better cognitive improvement
  7. Better tolerability and compliance overall
Disadvantages of atypicals:
  • Greater metabolic side effects (weight gain, diabetes, dyslipidaemia)
  • Clozapine: agranulocytosis risk
  • More expensive

Q. Compare and Contrast Typical and Atypical Antipsychotic Agents

FeatureTypical (1st gen)Atypical (2nd gen)
Primary receptorD2 blockade (high affinity, >80% occupancy)D2 + 5-HT2A blockade (D2 occupancy 60-70%)
Positive symptoms✓✓ Effective✓✓ Effective
Negative symptomsPoor / ineffectiveBetter efficacy
EPSHigh risk (dystonia, akathisia, parkinsonism)Low risk
Tardive dyskinesiaHigh riskLow risk
Prolactin elevationHighLow (except Risperidone, Amisulpride)
Metabolic effectsLessMore (weight gain, DM, dyslipidaemia)
QTc prolongationThioridazine >> othersZiprasidone, Amisulpride
AgranulocytosisRareClozapine (1-2%)
Treatment-resistant schizophreniaLess effectiveClozapine effective
ExamplesHaloperidol, ChlorpromazineClozapine, Olanzapine, Risperidone

Q. Pharmacological Basis of Haloperidol; Advantages of Atypical over Typical; Typical Antipsychotic ADRs with Treatment (2023 June New - 19-yr male with acute psychosis)

Pharmacological Basis of Haloperidol:
  • Haloperidol is a butyrophenone - potent, selective D2 receptor antagonist.
  • Blocks mesolimbic dopamine pathway → reduces positive symptoms (hallucinations, delusions).
  • Also blocks D2 in nigrostriatal pathway → EPS; in tuberoinfundibular pathway → hyperprolactinaemia; in CTZ → antiemetic.
  • Has some alpha-1 adrenergic and H1 blocking properties.
Advantages of Atypical: (Covered above)
ADRs of Typical Antipsychotics and Treatment:
  • Acute dystonia → IM Benztropine or IV Diphenhydramine
  • Akathisia → Propranolol 20-40 mg/day, Benzodiazepines
  • Drug-induced Parkinsonism → Trihexyphenidyl, Benztropine, Amantadine
  • Tardive Dyskinesia → Valbenazine, Deutetrabenazine (VMAT2 inhibitors); reduce/switch antipsychotic
  • NMS → Dantrolene, Bromocriptine, intensive supportive care

Q. Classify Antipsychotics; Long-Acting Injectables (LAI); Mechanism/Uses/ADRs of Haloperidol; Compare Haloperidol vs Olanzapine (2024 August)

Long-Acting Injectable (LAI) Antipsychotics:
  • Haloperidol decanoate (monthly IM)
  • Fluphenazine decanoate (2-3 weekly IM)
  • Risperidone microspheres (Risperdal Consta - 2 weekly IM)
  • Paliperidone palmitate (Invega Trinza - monthly or 3-monthly)
  • Olanzapine pamoate (monthly IM - requires 3-hr monitoring for post-injection syndrome)
  • Aripiprazole lauroxil (monthly/2-monthly)
Advantage of LAI: Ensures compliance; avoids daily oral dosing; stable plasma levels.
Haloperidol vs Olanzapine:
FeatureHaloperidolOlanzapine
ClassTypical (butyrophenone)Atypical (thienobenzodiazepine)
MechanismD2 blockadeD2 + 5-HT2A + H1 + M1 + alpha1 blockade
Positive symptoms✓✓✓✓
Negative symptomsPoor✓✓
EPSHighLow
Weight gainMinimalHigh (most weight gain of all antipsychotics after Clozapine)
SedationModerateHigh (H1 blockade)
QTcModerate prolongationMinimal
Metabolic syndromeMinimalHigh risk
ProlactinHigh elevationMinimal elevation

Q. Weight-Neutral Antipsychotics

Antipsychotics with minimal or no weight gain:
  1. Ziprasidone
  2. Aripiprazole (actually may cause slight weight loss)
  3. Amisulpride
  4. Lurasidone
  5. Haloperidol (typical, minimal weight gain)
Heaviest weight gain: Clozapine > Olanzapine > Quetiapine > Risperidone

Q. Enumerate Extrapyramidal Side Effects of Typical Neuroleptics

  1. Acute dystonia - within 1-5 days; sustained involuntary muscle contractions (torticollis, oculogyric crisis, opisthotonus, trismus, laryngospasm)
  2. Akathisia - within days to weeks; subjective restlessness, compulsion to move
  3. Drug-induced parkinsonism - within weeks to months; tremor, rigidity, bradykinesia, mask-like face
  4. Tardive dyskinesia (TD) - after months to years of use; involuntary orofacial/choreiform movements; may be irreversible
  5. Rabbit syndrome - fine perioral tremor (late onset, distinct from TD)
  6. Tardive dystonia - late-onset dystonic movements
  7. Tardive akathisia

Q. Rationale of Using Samidorphan with Olanzapine in Schizophrenia (2025 Jan)

Lybalvi = Olanzapine + Samidorphan (FDA approved combination)
Samidorphan:
  • A mu-opioid receptor antagonist (partial antagonist).
  • The mu-opioid system is involved in appetite regulation, food reward, and weight gain.
  • Olanzapine causes weight gain partly through mu-opioid receptor activation (increasing appetite and food intake).
  • Samidorphan blocks mu-opioid receptors → mitigates olanzapine-induced weight gain.
  • Does not affect the antipsychotic efficacy of olanzapine.
  • Also reduces metabolic side effects (dyslipidaemia, glucose intolerance).
  • Note: Samidorphan is NOT the same as Naltrexone (though both are opioid antagonists); Samidorphan has a different CNS distribution profile.

CHAPTER: ANTIDEPRESSANTS & ANTI-ANXIETY DRUGS

Q. Why are SSRIs Preferred for Treatment of Depression?

SSRIs (Selective Serotonin Reuptake Inhibitors): Fluoxetine, Sertraline, Paroxetine, Fluvoxamine, Citalopram, Escitalopram
Mechanism: Block presynaptic serotonin reuptake transporter (SERT) → increased serotonin in synaptic cleft.
Why preferred:
  1. Greater safety: Much wider therapeutic index compared to TCAs; SSRIs rarely cause fatal overdose.
  2. Fewer anticholinergic effects: No dry mouth, constipation, urinary retention, blurred vision (TCAs have significant anticholinergic effects).
  3. No cardiotoxicity: TCAs cause QTc prolongation and arrhythmias; SSRIs are much safer in cardiac patients.
  4. No orthostatic hypotension (unlike TCAs and MAOIs).
  5. No sedation (non-sedating; patients can function normally).
  6. No weight gain (unlike TCAs and mirtazapine).
  7. Once-daily dosing - better compliance.
  8. Broader indications: Effective for depression, anxiety disorders, OCD, PTSD, panic disorder, bulimia, social phobia.
  9. Better tolerated by elderly patients.
  10. No strict dietary restrictions (unlike MAOIs - tyramine diet).
Side effects of SSRIs: GI disturbances (nausea, diarrhoea), sexual dysfunction (most common persistent side effect), insomnia, serotonin syndrome (if combined with other serotonergic drugs), SSRI discontinuation syndrome (especially Paroxetine), hyponatraemia (elderly).

Q. Enumerate SSRIs and Write Rationale for Use of Fluoxetine in Depression

SSRIs:
  1. Fluoxetine (Prozac) - longest half-life (1-4 days; active metabolite Norfluoxetine ~5-15 days)
  2. Sertraline
  3. Paroxetine (shortest half-life; most anticholinergic of the SSRIs; most discontinuation syndrome)
  4. Fluvoxamine (used mainly for OCD)
  5. Citalopram
  6. Escitalopram (S-enantiomer of citalopram; most selective)
Rationale for Fluoxetine in Depression:
  • Selectively inhibits SERT → increases serotonergic neurotransmission in limbic system (mediates mood).
  • Very long half-life (~1-4 days for parent; ~5-15 days for norfluoxetine) → virtually no discontinuation syndrome, convenient once-daily dosing, no dose tapering needed.
  • Activating (not sedating) → helps with psychomotor retardation in depression.
  • Effective for comorbid anxiety, OCD, bulimia nervosa, PMDD.
  • Also approved for bipolar depression (in combination with Olanzapine - Symbyax).

Q. Two SSRIs Used as Antidepressants (Very Short)

  1. Fluoxetine (Prozac)
  2. Sertraline (Zoloft)
(Also: Escitalopram, Paroxetine, Citalopram)

Q. Drugs for Treatment of Mania / Rationale of Lithium in Mania

Drugs for Mania:
  1. Lithium carbonate (drug of choice for classical bipolar mania; also prophylaxis)
  2. Valproate (sodium valproate) - rapid-cycling, mixed episodes
  3. Carbamazepine - rapid-cycling
  4. Antipsychotics (acute mania): Haloperidol, Olanzapine, Risperidone, Quetiapine, Aripiprazole
  5. Benzodiazepines (adjunct for acute agitation): Lorazepam, Clonazepam
Rationale of Lithium in Mania:
Lithium's mechanisms (multiple, not fully elucidated):
  1. Inositol depletion hypothesis (main): Lithium inhibits inositol monophosphatase → depletes free inositol → reduces phosphatidylinositol (PI) signalling → dampens neuronal excitability in pathways relying on IP3/DAG signalling.
  2. GSK-3β inhibition: Lithium is a direct inhibitor of glycogen synthase kinase-3β → affects gene expression, neuroprotection, circadian rhythms.
  3. Protein kinase C (PKC) inhibition: Reduces signal transduction in manic state.
  4. Modulates monoamine neurotransmission: Reduces noradrenaline and dopamine turnover; increases serotonin synthesis.
  5. Affects adenylyl cyclase signalling.
Lithium uses: Acute mania (takes 1-2 weeks; antipsychotics used for acute control), Prophylaxis of bipolar disorder (both manic and depressive episodes), Treatment of bipolar depression, Augmentation of antidepressants in refractory depression, Recurrent unipolar depression prophylaxis.
Lithium toxicity (narrow therapeutic window; target serum level 0.8-1.2 mEq/L):
  • Mild: Fine tremor, polyuria, polydipsia, nausea, diarrhoea
  • Moderate: Coarse tremor, ataxia, confusion, drowsiness
  • Severe: Seizures, coma, cardiac arrhythmias
  • Chronic: Nephrogenic diabetes insipidus, hypothyroidism, hyperparathyroidism

CHAPTER: OPIOID ANALGESICS AND ANTAGONISTS

Q. Enumerate Opioid Analgesics; Mechanism of Action, Uses, and Side Effects

Classification / Enumeration of Opioid Analgesics

Strong opioids (µ agonists):
  • Morphine (standard); Diamorphine (Heroin); Oxycodone; Hydromorphone; Methadone; Fentanyl (+ Sufentanil, Alfentanil, Remifentanil for anaesthesia)
Moderate opioids:
  • Codeine; Tramadol (weak µ agonist + SNRI); Tapentadol; Buprenorphine (partial µ agonist, κ antagonist); Pentazocine (κ agonist, weak µ antagonist)
Opioid antagonists:
  • Naloxone (pure antagonist, IV - short-acting reversal); Naltrexone (oral, long-acting); Methylnaltrexone (peripheral only, for opioid-induced constipation)
Mixed agonist-antagonists: Buprenorphine, Pentazocine, Nalbuphine, Butorphanol

Mechanism of Action of Opioids

Opioids act on G-protein coupled opioid receptors:
  • µ (mu) - MOR: Main analgesic receptor; located in PAG (periaqueductal grey), dorsal horn, limbic system, peripheral sensory neurons
  • κ (kappa) - KOR: Spinal analgesia, sedation, dysphoria, miosis
  • δ (delta) - DOR: Spinal and supraspinal analgesia, mood modulation
Mechanism:
  1. Opioids → activate Gi/Go proteins → inhibit adenylyl cyclase → ↓ cAMP
  2. ↑ K⁺ conductance (hyperpolarization) → reduced neuronal firing
  3. Inhibit voltage-gated Ca²⁺ channels (presynaptic) → ↓ neurotransmitter release (especially substance P, glutamate)
  4. Net result: Inhibit pain transmission in spinal cord (dorsal horn), activate descending inhibitory pathways, and alter perception in brain.

Uses of Morphine / Opioids

  1. Analgesia: Severe acute pain (post-operative, trauma), chronic cancer pain, MI pain (morphine + antiemetic)
  2. Acute pulmonary oedema: Morphine IV - reduces preload (venodilation), reduces anxiety/respiratory distress
  3. Cough suppression: Codeine, Pholcodine (antitussive)
  4. Diarrhoea: Loperamide (peripheral only), Diphenoxylate + atropine (Lomotil)
  5. Pre-anaesthetic medication: Morphine for its analgesic/sedative effect
  6. Opioid substitution therapy: Methadone or Buprenorphine in opioid dependence
  7. Dyspnoea in terminal illness (palliative care)

Side Effects of Opioids

  1. CNS: Sedation, euphoria, miosis (pin-point pupils - hallmark of overdose), respiratory depression (main cause of death in overdose), nausea/vomiting (CTZ stimulation)
  2. GI: Constipation (most persistent side effect; no tolerance develops), biliary colic (Oddi's sphincter spasm)
  3. CVS: Hypotension (histamine release), bradycardia
  4. Urinary retention (sphincter contraction)
  5. Physical dependence and addiction
  6. Tolerance (except constipation and miosis)
  7. Pruritus (histamine release with morphine; more with spinal opioids)
  8. Neonatal respiratory depression (if given to mother near delivery)

Q. Opioid Antagonists

  1. Naloxone (Narcan):
    • Pure competitive antagonist at µ, κ, δ receptors
    • Given IV/IM/IN; onset within 2 minutes
    • Half-life short (30-90 min) - shorter than most opioids → repeat doses may be needed
    • Uses: Opioid overdose reversal (emergency); reversal of post-operative opioid respiratory depression; diagnosis of opioid dependence
    • Does NOT cross oral bioavailability well → only IV/IM/intranasal
    • Can precipitate acute withdrawal in opioid-dependent patients
  2. Naltrexone:
    • Oral, long-acting (half-life ~4 hrs; active metabolite 6-beta-naltrexol ~13 hrs)
    • Uses: Opioid deaddiction/relapse prevention; alcohol dependence (reduces craving)
    • Given after complete opioid detox (otherwise precipitates severe withdrawal)
  3. Methylnaltrexone (Relistor):
    • Quaternary compound - does NOT cross BBB
    • Selectively reverses peripheral µ receptor effects (constipation, urinary retention)
    • Without reversing central analgesia or causing withdrawal
    • Use: Opioid-induced constipation in palliative care
  4. Naloxegol: Similar peripheral opioid antagonist (oral) for opioid-induced constipation.

Q. Two Drugs for Opioid Deaddiction

  1. Methadone - long-acting oral µ agonist; prevents withdrawal, reduces craving; also blocks euphoria from additional opioids
  2. Buprenorphine (+ Naloxone as Suboxone) - partial µ agonist + κ antagonist; ceiling effect on respiratory depression; sublingual; prevents withdrawal and abuse

Q. Why is Morphine Contraindicated in Head Injury Patients?

  1. CO₂ retention → cerebral vasodilation → raised ICP:
    • Morphine causes respiratory depression → ↓ respiratory rate → ↑ PaCO₂ (hypercapnia) → cerebral vasodilation → ↑ cerebral blood flow → ↑ intracranial pressure (ICP)
    • In head injury, ICP is already elevated; further rise is dangerous (herniation risk)
  2. Pupillary changes mask neurological assessment:
    • Morphine causes miosis (pin-point pupils)
    • Pupillary reactions are critical in monitoring neurological deterioration in head injury
    • Morphine masks this vital sign
  3. Sedation/altered consciousness:
    • Morphine-induced sedation makes it difficult to assess the level of consciousness (GCS)
  4. CNS depressant effect:
    • Worsens CNS depression already present due to head injury
  5. Histamine release:
    • Morphine releases histamine → vasodilation → can worsen hypotension, affecting cerebral perfusion pressure.

Q. Two Contraindications of Morphine (2023 June Old)

  1. Head injury / raised intracranial pressure (as above)
  2. Acute severe bronchial asthma (histamine release → bronchoconstriction + respiratory depression)
Other important contraindications: Acute alcoholism, concurrent MAOIs (serotonin syndrome/opioid toxicity), chronic obstructive lung disease with respiratory failure, paralytic ileus.
---I can see the PDF has already been read. Let me continue with the remaining sections - Sections II through VI.
This is a shared conversation. Sign in to Orris to start your own chat.